French SAGhE Study: Long-Term Mortality After Childhood Recombinant Growth Hormone Treatment
By
Carel, Jean-Claude, Ecosse, Emmanuel, Landier, Fabienne, Meguellati-Hakkas, Djamila, Kaguelidou, Florentia, Rey, Grégoire, Coste, Joël
Summary
This preliminary report from the French SAGhE study examines long-term mortality risks in subjects who received recombinant growth hormone (GH) treatment during childhood for isolated growth hormone deficiency or idiopathic short stature. The study investigates the safety and long-term health outcomes of GH treatment, addressing concerns about potential increased mortality risks associated with this therapy.
Source

Key quotes
· 2 pulledLittle is known about the long-term health of subjects treated with GH in childhood
Safety and Appropriateness of Growth hormone treatments
You might also wanna read

Study Examines Association Between mRNA COVID-19 Vaccination and 4-Year All-Cause Mortality in French Adults Aged 18-59
This cohort study analyzes data from over 28 million French adults aged 18-59 to examine the association between mRNA COVID-19 vaccination a
Growth Hormone Therapy for Hypochondroplasia
Third Death in Sarepta Gene Therapy Trial for Limb-Girdle Muscular Dystrophy
A 51-year-old patient in a Phase I study of Sarepta's gene therapy for Limb-Girdle muscular dystrophy Type 2E has died from acute liver toxi
How to Navigate Persistent Acromegaly After Surgery
Study Finds Children with MIS-C Face Significantly Higher Long-Term Health Risks Years After COVID-19
A study of 173 children with MIS-C (multisystem inflammatory syndrome in children) compared to 14,190 without MIS-C, tracked up to 4.5 years

One-Time Gene Therapy Restores Vision in 6-Year-Old with Rare Congenital Blindness
A 6-year-old girl named Saffie Sandford from Stevenage, UK, has had her vision saved through a one-time gene therapy for Leber's Congenital
goodnewsnetwork.org·18d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.